Researchers explore patient’s perceptions of AI in radiology

Af­ter years of try­ing to ex­pand the mar­ket ter­ri­to­ry for Nu­plazid, Aca­dia Phar­ma­ceu­ti­cals might have hit a dead end, with a Phase III fail­ure in

Aerovate Ther­a­peu­tics’ mid-stage treat­ment for pul­monary ar­te­r­i­al hy­per­ten­sion failed to mean­ing­ful­ly im­prove pa­tients’ blood pres­sure com­pared to place­bo across three dos­es, send­ing the com­pa­ny’s shares